Update on HHV-8-associated malignancies

Current Infectious Disease Reports

Volumn 12, Issue 2, 2010, Pages 147-154

  Sunil, Meena ^a   Reid, Erin ^b   Lechowicz, Mary Jo ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HHV 8; Human herpesvirus 8; Kaposi's sarcoma; KSHV; Multicentric Castleman's disease; Primary effusion lymphoma

Indexed keywords

BORTEZOMIB; CIDOFOVIR; CYCLINE; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR; GANCICLOVIR; INCYCLINIDE; LATENCY ASSOCIATED NUCLEAR ANTIGEN; MICRORNA; RAPAMYCIN; RITUXIMAB; THALIDOMIDE; TOCILIZUMAB; VALGANCICLOVIR; VALPROIC ACID;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CANCER INCIDENCE; CARCINOGENESIS; CARCINOGENICITY; CLINICAL TRIAL; DRUG DOSE COMPARISON; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOSURVEILLANCE; KAPOSI SARCOMA; MOLECULAR BIOLOGY; MOLECULAR MIMICRY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; REVIEW; SIGNAL TRANSDUCTION; VIRUS TRANSMISSION;

EID: 77953536922     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0092-5     Document Type: Review

References (74)

1. Hymes KB, Cheung T, Greene JB, et al.: Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 1981, 318:598-600.
2. Beral V, Peterman TA, Berkelman RL, et al.: Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 1990, 335:123-128.
3. Chang Y, Cesarman E, Pessin MS, et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
4. Cesarman E, ChangY,Moore PS, et al.:Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332:1186-1191.
5. Soulier J, Grollet L, Oksenhendler E, et al.: Kaposi's sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1276-1280.
6. Dupin N, Diss TL, Kellam P, et al.: HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV- 8-positive plasmablastic lymphoma. Blood 2000, 95:1406-1412.
7. Du MQ, Diss TC, Liu H, et al.: KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002, 100:3415-3418.
8. Ferry JA, Sohani AR, Longtine JA, et al.: HHV8-positive, EBVpositive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma. Mod Pathol 2009, 22:618-626
9. Pica F, Volpi A: Transmission of human herpesvirus 8: An update. Curr Opin Infect Dis 2007, 20:152-156. The review covers recent findings in the possible routes of HHV-8 transmission. The interaction of host genetic factors and control ofHHV-8 infection are briefly described.
10. Engels EA, Atkinson JO, Graubard BI, et al.: Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007, 196: 199-207. This is the first reported population-based cross-sectional study to evaluate the epidemiology of HHV-8 in the general US adult population. This study was undertaken by the National Health and Nutrition Examination Survey III.
11. Batista MD, Ferreira S, Sauer MM, et al.: High human herpesvirus 8 (HHV-8) prevalence, clinical correlates and high incidence among recently HIV-1 infected subjects in Sao Paulo, Brazil. PLoS One 2009, 4:e5613.
12. Butler LM, Dorsey G, Hladik W, et al.: Kaposi sarcomaassociated herpesvirus (KSHV) seroprevalence in populationbased samples of African children: Evidence for at least 2 patterns of KSHV transmission. J Infect Dis 2009, 200:430-438.
13. Minhas V, Crabtree KL, Chao A, et al.: Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol 2008, 168:311-320.
14. Luppi M, Barozzi P, Santagostino G, et al.: Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000, 96:3279-3281.
15. Einollahi B, Lessan-Pezeshki M, Nourbala MH, et al.: Kaposi's sarcoma following living donor kidney transplantation: Review of 7,939 recipients. Int Urol Nephrol 2009, 41:679-685.
16. Liang C, Lee JS, Jung JU: Immune evasion in Kaposi's sarcoma-associated herpesvirus-associated oncogenesis. Semin Cancer Biol 2008, 18:423-436. This review provides insight into the interplay between HHV-8 and the host immune system. The role of HHV-8 in tumorigenesis and in evasion of immune surveillance is elaborated.
17. Wen KW, Damania B: Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett 2009 (Epub ahead of print). This review article provides an in-depth look at the virus biology and its oncopathogenesis. The therapeutic strategies for HHV-8-associated disorders are also briefly described.
18. Sullivan RJ, Pantanowitz L, Casper C, et al.: HIV/AIDS: Epidemiology, pathophysiology, and treatment of Kaposi sarcomaassociated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008, 47:1209-1215. The basics of epidemiology, virology, and immunologic aspects of HHV-8 and its associated neoplasms are discussed in this article. Recent findings and various molecular targets of therapy are highlighted.
19. Abe Y, Matsubara D, Gatanaga H, et al.: Distinct expression of Kaposi's sarcoma-associated herpesvirus encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease. Pathol Int 2006, 56:617-624.
20. Zaldumbide A, Ossevoort M, Wiertz EJ, et al.: In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpesvirus. Mol Immunol 2007, 44:1352-1360.
21. Di Bartolo DL, Cannon M, Liu YF, et al.: KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 2008, 111:4731-4740.
22. Cai QL, Knight JS, Verma SC, et al.: EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2006, 2:e116.
23. Koopal S, Furuhjelm JH, Jarviluoma A, et al.: Viral oncogeneinduced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog 2007, 3:1348-1360.
24. Ye FC, Zhou FC, Xie JP, et al.: Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: A novel mechanism of virus control of latency. J Virol 2008, 82:4235-4249.
25. Grossman C, Ganem D: Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and contextdependent. Virology 2008, 375:94-102.
26. Lagos D, Trotter MW, Vart RJ, et al.: Kaposi sarcoma herpesvirusencoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood 2007, 109:1550-1558.
27. Sodhi A, Chaisuparat R, Hu J, et al.: TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcomaassociated herpesvirus G protein-coupled receptor. Cancer Cell 2006, 10:133-143.
28. Cullen BR: Viruses and microRNAs. Nat Genet 2006, 38(Suppl): S25-S30.
29. Skalsky RL, Samols MA, Plaisance KB, et al.: Kaposi's sarcomaassociated herpesvirus encodes an ortholog of miR-155. J Virol 2007, 81:12836-12845.
30. Gottwein E, Mukherjee N, Sachse C, et al.: A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450:1096-1099.
31. Thai TH, Calado DP, Casola S, et al.: Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
32. Samols MA, Skalsky RL, Maldonado AM, et al.: Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog 2007, 3:e65.
33. Munoz-Fontela C, Marcos-Villar L, Hernandez F, et al.: Induction of paclitaxel resistance by the kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Virol 2008, 82:1518-1525.
34. Zong JC, Ciufo DM, Alcendor DJ, et al. High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J Virol 1999, 73:4156-4170.
35. Mancuso R, Biffi R, Valli M, et al.: HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. J Med Virol 2008, 80:2153-2160.
36. Brown EE, Fallin MD, Goedert JJ, et al.: Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis 2006, 193:1054-1062.
37. Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187-194. This study highlights the persistence of KS in the HAART era in HIV-infected patients. The study evaluates the risk of malignancy in the moderately immunosuppressed HIV population.
38. Guihot A, Dupin N, Marcelin AG, et al.: Low T-cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006, 194:1078-1088.
39. National Cancer Institute: SEER Cancer statistics review 1975- 2004. Available at http://seer.cancer.gov/csr/1975-2004/results-merged/sect-10-kaposi- sarcoma.pdf Accessed November 2009.
40. Martro E, Esteve A, Schulz TF, et al.: Risk factors for human herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicenter study. Int J Cancer 2007, 120:1129-1135. This European multicenter study shows evidence of high prevalence of HHV- 8 seropositivity among MSM. Low CD4 counts and lack of HAART were shown to be significant risk factors in development of KS.
41. Maurer T, Ponte M, Leslie K: HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007, 357:1352-1353.
42. Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008, 358:535-536.
43. El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al.: Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008, 22:1019-1028.
44. Nguyen HQ, Magaret AS, Kitahata MM, et al.: Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: Characterizing the predictors of clinical response. AIDS 2008, 22:937-945.
45. Laney AS, Cannon MJ, Jaffe HW, et al.: Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS 2007, 21:1541-1545.
46. Nsubuga MM, Biggar RJ, Combs S, et al.: Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions. Cancer Lett 2008, 263:182-188.
47. Stebbing J, Sanitt A, Nelson M, et al.: A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006, 367:1495-1502.
48. Stallone G, Schena A, Infante B, et al.: Sirolimus for Kaposi's sarcoma in renal-transplant recepients. N Engl J Med 2005, 352:1317-1323.
49. Barozzi P, Bonini C, Potenza L, et al.: Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008, 86:738-744.
50. Ho CM, Huang SF, Hu RH, et al.: Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient. Clin Transplant 2009 (Epub ahead of print).
51. Monaco AP: The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87:157-163.
52. Dezube BJ, Krown SE, Lee JY, et al.: Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 2006, 24:1389-1394.
53. Lechowicz M, Dittmer DP, Lee JY, et al.: Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic acid. Clin Infect Dis 2009 (Epub ahead of print).
54. Stebbing J, Pantanowitz L, Dayyani F, et al.: HIV-associated multicentric Castleman's disease. Am J Hematol 2008, 83:498- 503. This article presents a comprehensive review of the pathogenesis, presentation, and treatment options of the rare lymphoproliferative disorder, MCD.
55. Naresh KN, Rice AJ, Bower M: Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol 2008, 32:1006-1012.
56. Kim B, Jeon YK, Kim CW: Kaposi sarcoma herpes virusassociated hemophagocytic syndrome complicated by multicentric Castleman disease and Kaposi sarcoma in a HIV-negative immunocompetent patient: An autopsy case. J Korean Med Sci 2009, 24: 970-974.
57. Wyplosz B, Carlotti A, Escaut l, et al.: Initial human herpesvirus- 8 rash and multicentric Castleman disease. Clin Infect Dis 2008, 47:684-688.
58. Seliem RM, Griffith RC, Harris NL, et al.: HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ man: The spectrum of HHV-8+ lymphoproliferative disorders expands. Am J Surg Pathol 2007, 31:1439-1445.
59. Stary G, Kohrgruber N, Herneth AM, et al.: Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 2008, 22:1232-1234.
60. Bower M, Powles T, Williams S, et al.: Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007, 147:836-839.
61. Gerard L, Berezne A, Galicier L, et al.: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB trial. J Clin Oncol 2007, 25:3350-3356. This article presents the first reported prospective therapeutic trial of HIVrelated MCD. The results affirm the role of rituximab as an efficacious therapeutic agent for MCD.
62. Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol 2008, 140:13-24.
63. Boulanger E, Afonso PV, Yahiaoui Y, et al.: Human herpesvirus- 8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008, 8:707-710.
64. Melo NC, Sales MM, Santana AN, et al.: Pleural primary effusion lymphoma in a renal transplant recipient. Am J Transplant 2008, 8:906-907.
65. Wu SJ, Hung CC, Chen CH, et al.: Primary effusion lymphoma in three patients with chronic hepatitis B infection. J Clin Virol 2009, 44:81-83.
66. Brimo F, Michel RP, Khetani K, et al.: Primary effusion lymphoma: A series of 4 cases and review of literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007, 111:224-233.
67. De Filippi R, Laccarino G, Frigeri F, et al.: Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol 2009, 147:405-408.
68. Gasperini P, Tosato G: Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia 2009, 23:1867-1874.
69. Boulanger E, Meignin V, Oksenhendler E: Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 2008, 141:559-561.
70. Ripamonti D, Marini B, Rambaldi A, et al.: Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS 2008, 22:1236-1237.
71. Cassoni A, Ali U, Cave J, et al.: Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol 2008, 26:5297-5299.
72. Casper C, Krantz EM, Corey L, et al.: Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008, 198:23-30.
73. Nun TK, Kroll DJ, Oberlies NH, et al.: Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther 2007, 6:2360-2370.
74. Bryant A, Milliken S: Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 2008, 14:601-602.